Results 111 to 120 of about 11,948 (164)

Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease. [PDF]

Arthritis Res Ther
Zhu S, Li S, Shi L, Chu T, Huang Z, Lu X, Wang G, Ge Y.   +7 more
europepmc   +1 more source

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry. [PDF]

Allergy
van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacoş-Cosma O, Loman L, Atash K, Harbers V, Stadhouders S, Oosting AJ, van Lynden-van Nes AMT, Politiek K, Gostynski A, Christoffers WA, Garritsen FM, Flinterman A, Touwslager WRH, Velstra B, Stewart SM, van Erp FC, Galimont-Collen AFS, Schuttelaar MA, de Graaf M, de Bruin-Weller MS.   +23 more
europepmc   +1 more source

Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib. [PDF]

Front Med (Lausanne)
Lv X, Chen Y, Ruan SF, Xu Q, Mao J, Zhu L, Xia W, Bao S, Zhuang Z, Chen L, Cheng B, Ji C.   +11 more
europepmc   +1 more source

T-cell-predominant inflammation in livedoid vasculopathy and response to baricitinib. [PDF]

JAAD Int
Wei DD, Nong ZX, Huang D, Wang SF, Huang KQ, Wen SJ.   +5 more
europepmc   +1 more source

Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data. [PDF]

Front Immunol
Lee YJ, Choi G, Yeo J, Baek J, Choi H, Kim M, Kim YG, Kim BY, Koo J.   +8 more
europepmc   +1 more source

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti-MDA5 Dermatomyositis-Related Interstitial Lung Disease: A Pilot Study. [PDF]

ACR Open Rheumatol
Matsuo H, Koga T, Shimizu T, Ide H, Koto S, Kojima K, Fujita Y, Okamoto M, Takatani A, Suzuki T, Matsushita Y, Kawakami A.   +11 more
europepmc   +1 more source

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study. [PDF]

Rheumatol Ther
Alten R, Östör A, Edwards CJ, Smolen JS, Haladyj E, Ng KJ, Ogwu S, Kaneko Y.   +7 more
europepmc   +1 more source

A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes. [PDF]

J Clin Med
Lambiase S, Cavalloro D, Cioni A, Matteini E, Artosi F, Poscente F, Belardi R, Terrinoni A, Bernardini S, Bianchi L, Campione E, Diluvio L.   +11 more
europepmc   +1 more source

From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatment. [PDF]

Front Med (Lausanne)
Bonfiglioli KR.
europepmc   +1 more source

A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis. [PDF]

Clin Pharmacokinet
Decker RL, Ernest CS, Radtke DB, Prakash A, Zhang X.   +4 more
europepmc   +1 more source